Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 28 | 1,451 | 44% |
| 2020 | 23 | 1,360 | 46% |
| 2021 | 29 |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in Arizona; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 119 | 8,499+11%/yr | +11%/yr | 2.6 | 2% | 16,800 in 2030+12%/yr |
| Washington | 31 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 351 | 76,510−1%/yr | −1%/yr | 107.41.0× | 56% | 84,500 in 2030+1.7%/yr |
| ERCP & endoscopic ultrasound |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
| 2024 |
| 3,079 |
| 54% |
| 2025 est. | ≈ 3,500 | – |
| 2026 est. | ≈ 3,860 | – |
| 1,674 |
| 49% |
| 2022 | 26 | 1,860 | 51% |
| 2023 | 37 | 2,530 | 53% |
| 2024 | 38 | 3,079 | 54% |
| 2025 from claims | – | 3,501 3,213–3,704 | 55% |
| 2026 forecast | – | 3,857 3,394–4,451 | 55% |
| 2027 forecast | – | 4,232 3,618–5,044 | 56% |
| 2028 forecast | – | 4,643 3,874–5,686 | 56% |
| 2029 forecast | – | 5,094 4,161–6,388 | 57% |
| 2030 forecast | – | 5,588 4,477–7,161 | 57% |
In 2025, 24% inpatient hospital, 76% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~3,900 | ~920 | ~2,900 |
| 2027 · ~4,200 | ~990 | ~3,200 |
| 2028 · ~4,600 | ~1,100 | ~3,600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 23% (24% in 2025), hospital outpatient about 77% (76% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 1,779+2.1%/yr |
| +2.1%/yr |
| 2.3 |
| 0% |
| 2,570 in 2030+6.3%/yr |
| Colorado | 18 | 1,328+5.9%/yr | +5.9%/yr | 2.8 | 0% | 2,020 in 2030+7.2%/yr |
| Oregon | 10 | 796+5.6%/yr | +5.6%/yr | 1.9 | 0% | 1,500 in 2030+11%/yr |
| Nevada | 11 | 545+13%/yr | +13%/yr | 1.9 | 0% | 870 in 2030+8.2%/yr |
| Utah | 6 | 444+15%/yr | +15%/yr | 2.1 | 0% | 960 in 2030+14%/yr |
| Idaho | 5 | 286+3%/yr | +3%/yr | 1.4 | 0% | 650 in 2030+15%/yr |
| Montana | 5 | 277+1.2%/yr | +1.2%/yr | 1.5 | 0% | 310 in 2030+1.7%/yr |
| Hawaii | 6 | 241+24%/yr | +24%/yr | 1.9 | 0% | 590 in 2030+16%/yr |
| New Mexico | 4 | 210+8.1%/yr | +8.1%/yr | 0.9 | 0% | 570 in 2030+18%/yr |
| Alaska | 2 | 179+25%/yr | +25%/yr | 1.5 | 0% | 660 in 2030+24%/yr |
| 36 |
| 2,770+2.8%/yr |
| +2.8%/yr |
| 3.81.1× |
| 2% |
| 3,300 in 2030+3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Merit Medical Systems leads with 25% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 20 companies reported engagement with Arizona’s surgeons worth $130K in consulting, speaking, meals and travel tied to these products, about $3,411 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.